BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Naeshiro N, Kakizawa H, Aikata H, Kan H, Fujino H, Fukuhara T, Kobayashi T, Honda Y, Miyaki D, Kawaoka T, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Hyogo H, Ishikawa M, Awai K, Chayama K. Percutaneous transvenous embolization for portosystemic shunts associated with encephalopathy: Long-term outcomes in 14 patients. Hepatol Res 2014;44:740-9. [PMID: 23745735 DOI: 10.1111/hepr.12181] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Lynn AM, Leise MD. Reply. Liver Transpl 2016;22:1736-7. [PMID: 27731936 DOI: 10.1002/lt.24647] [Reference Citation Analysis]
2 Elwir S, Rahimi RS. Hepatic Encephalopathy: An Update on the Pathophysiology and Therapeutic Options. J Clin Transl Hepatol. 2017;5:142-151. [PMID: 28660152 DOI: 10.14218/jcth.2016.00069] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
3 Byrne MJ, Kaye DM. Cardiac Gene Delivery Using Recirculating Devices. Methods Mol Biol 2017;1521:261-9. [PMID: 27910056 DOI: 10.1007/978-1-4939-6588-5_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Namba M, Kawaoka T, Aikata H, Kodama K, Uchikawa S, Ohya K, Morio K, Fujino H, Nakahara T, Murakami E, Yamauchi M, Tsuge M, Hiramatsu A, Imamura M, Baba Y, Awai K, Chayama K. Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt. Clin J Gastroenterol 2019;12:341-6. [PMID: 30706429 DOI: 10.1007/s12328-019-00938-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Le H, Thukral S, Devane AM, Saddekni S, Varma RK. Endovascular Management of Hepatic Encephalopathy. Journal of Clinical Interventional Radiology ISVIR 2021;5:106-15. [DOI: 10.1055/s-0041-1730869] [Reference Citation Analysis]
6 Borentain P, Soussan J, Resseguier N, Botta-Fridlund D, Dufour JC, Gérolami R, Vidal V. The presence of spontaneous portosystemic shunts increases the risk of complications after transjugular intrahepatic portosystemic shunt (TIPS) placement. Diagn Interv Imaging 2016;97:643-50. [PMID: 26947721 DOI: 10.1016/j.diii.2016.02.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
7 Vidal-González J, Quiroga S, Simón-Talero M, Genescà J. Spontaneous portosystemic shunts in liver cirrhosis: new approaches to an old problem. Therap Adv Gastroenterol 2020;13:1756284820961287. [PMID: 33062057 DOI: 10.1177/1756284820961287] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
8 Lynn AM, Singh S, Congly SE, Khemani D, Johnson DH, Wiesner RH, Kamath PS, Andrews JC, Leise MD. Embolization of portosystemic shunts for treatment of medically refractory hepatic encephalopathy. Liver Transpl 2016;22:723-31. [PMID: 26970243 DOI: 10.1002/lt.24440] [Cited by in Crossref: 39] [Cited by in F6Publishing: 23] [Article Influence: 7.8] [Reference Citation Analysis]
9 Berthod PE, Chevallier O, Latournerie M, Gehin S, Falvo N, Midulla M, Loffroy R. Atypical use of ALN inferior vena cava filters as protection devices prior to embolization of a large portosystemic shunt with Amplatzer Vascular Plugs and Glubran 2 cyanoacrylate glue. Quant Imaging Med Surg 2018;8:452-6. [PMID: 29928611 DOI: 10.21037/qims.2018.03.11] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Rajesh S, Philips CA, Ahamed R, Abduljaleel JK, Nair DC, Augustine P. Friend or Foe? Spontaneous Portosystemic Shunts in Cirrhosis-Current Understanding and Future Prospects. Can J Gastroenterol Hepatol 2021;2021:8795115. [PMID: 34422711 DOI: 10.1155/2021/8795115] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Nardelli S, Gioia S, Ridola L, Riggio O. Radiological Intervention for Shunt Related Encephalopathy. J Clin Exp Hepatol 2018;8:452-9. [PMID: 30564003 DOI: 10.1016/j.jceh.2018.04.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
12 Hyodo R, Takehara Y, Mizuno T, Ichikawa K, Ishizu Y, Sugiyama M, Naganawa S. Time-resolved 3D cine phase-contrast magnetic resonance imaging (4D-flow MRI) can quantitatively assess portosystemic shunt severity and confirm normalization of portal flow after embolization of large portosystemic shunts. Hepatol Res 2021;51:343-9. [PMID: 33434371 DOI: 10.1111/hepr.13616] [Reference Citation Analysis]
13 Philips CA, Rajesh S, Augustine P, Padsalgi G, Ahamed R. Portosystemic shunts and refractory hepatic encephalopathy: patient selection and current options. Hepat Med. 2019;11:23-34. [PMID: 30774483 DOI: 10.2147/hmer.s169024] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 5.3] [Reference Citation Analysis]
14 Mukund A, Chalamarla LK, Singla N, Shasthry SM, Sarin SK. Intractable hepatic encephalopathy in cirrhotic patients: mid-term efficacy of balloon-occluded retrograde portosystemic shunt obliteration. Eur Radiol 2020;30:3462-72. [PMID: 32048037 DOI: 10.1007/s00330-019-06644-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Philips CA, Kumar L, Augustine P. Shunt occlusion for portosystemic shunt syndrome related refractory hepatic encephalopathy-A single-center experience in 21 patients from Kerala. Indian J Gastroenterol. 2017;36:411-419. [PMID: 29124669 DOI: 10.1007/s12664-017-0787-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]